AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $207,339 | -38.4% | 20,130 | -1.4% | 0.00% | – |
| Q2 2023 | $336,324 | +137.6% | 20,408 | +32.1% | 0.00% | – |
| Q1 2023 | $141,522 | -30.5% | 15,450 | -45.7% | 0.00% | – |
| Q4 2022 | $203,702 | +42.4% | 28,450 | 0.0% | 0.00% | – |
| Q3 2022 | $143,000 | +90.7% | 28,450 | -7.8% | 0.00% | – |
| Q2 2022 | $75,000 | -50.0% | 30,850 | +40.5% | 0.00% | – |
| Q1 2022 | $150,000 | -5.1% | 21,950 | +12.3% | 0.00% | – |
| Q4 2021 | $158,000 | -15.1% | 19,550 | +3.2% | 0.00% | – |
| Q3 2021 | $186,000 | +44.2% | 18,950 | -1.0% | 0.00% | – |
| Q2 2021 | $129,000 | -11.6% | 19,150 | +18.6% | 0.00% | – |
| Q1 2021 | $146,000 | +114.7% | 16,150 | +57.6% | 0.00% | – |
| Q4 2020 | $68,000 | +21.4% | 10,250 | -7.2% | 0.00% | – |
| Q3 2020 | $56,000 | -47.7% | 11,050 | -16.2% | 0.00% | – |
| Q2 2020 | $107,000 | – | 13,183 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |